Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells

Molecular Pharmacology

Volumn 53, Issue 1, 1998, Pages 62-76

  Verdier Pinard, Pascal ^a   Lai, Jing Yu ^b   Yoo, Hae Dong ^c   Yu, Jurong ^b   Marquez, Brian ^c   Nagle, Dale G ^c   Nambu, Mitch ^c   White, James D ^c   Falck, J R ^b   Gerwick, William H ^c   Day, Billy W ^d   Hamel, Ernest ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CURACIN A; CURACIN A DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN MCF 7; COMPUTER MODEL; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TUMOR GROWTH;

EID: 0031913357     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.53.1.62     Document Type: Article

References (36)

1. Banerjee A, Barnes LD, and Ludueña RF (1987) The role of the B-ring of colchicine in the stability or the colchicine-tubulin complex. Biochim Biophys Acta 913:138-144.
2. Bhattacharyya B, Howard R, Maity SN, Brossi A, Sharma PN, and Wolff J (1986) B ring regulation of colchicine binding kinetics and fluorescence. Proc Natl Acad Sci USA 83:2052-2055.
3. Blokhin AV, Yoo H-D, Geralds RS, Nagle DG, Gerwick WH, and Hamel E (1995) Characterization of the interaction of the marine cyanobacterial natural product curacin A with the colchicine site of tubulin and initial structure-activity studies with analogs. Mol Pharmacol 48:523-531.
4. Del Re G (1958) A simple MO-LCAO method for the calculation of charge distributions in saturated organic molecules. J Chem Soc :4033-4040.
5. Fitzgerald TJ (1976) Molecular features of colchicine associated with antimitotic activity and inhibition of tubulin polymerization. Biochem Pharmacol 26:1383-1387.
6. Friedman J (1990) Technical report no. 102. Laboratory for Computational Statistics, Department of Statistics, Stanford University, Stanford, CA.
7. Gerwick WH, Proteau PJ, Nagle DG, Hamel E, Blokhin A, and Slate DL (1994) Structure of curacin A, a novel antimitotic, antiproliferative, and brine shrimp toxic natural product from the marine cyanobacterium Lyngbya majuscula. J Org Chem 59:1243-1245.
8. Hahn M and Rogers D (1995) Receptor surface models. 2. Application to quantitative structure-activity-relationships studies. J Med Chem 38:2091-2102.
9. Hamel E (1990) Interactions of tubulin with small ligands in Microtubule Proteins (Avila J, ed) pp 89-191, CRC Press, Boca Raton, FL.
10. Hamel E (1996) Antimitotic natural products and their interactions with tubulin. Med Res Rev 16:207-231.
11. Hamel E and Lin CM (1981) Stabilization of the colchicine-binding activity of tubulin by organic acids. Biochim Biophys Acta 675:226-231.
12. Hamel E and Lin CM (1984) Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. Biochemistry 23:4173-4184.
13. Hamel E, Blokhin AV, Nagle DG, Yoo H-D, and Gerwick WH (1995) Limitations in the use of tubulin polymerization assays as a screen for the identification of new antimitotic agents: the potent marine natural product curacin A as an example. Drug Dev Res 34:110-120.
14. Hansch C and Leo A (1979) Substituent Constants for Correlation Analysis in Chemistry and Biology. John Wiley and Sons, New York.
15. Hoemann MZ, Agrios KA, and Aube J (1996) Total synthesis of curacin A. Tetrahedron Lett 37:953-956.
16. Hopfinger AJ (1973) Conformational Properties of Macromolecules. Academic Press, New York.
17. Ito H, Imai N, Takao K, and Kobayashi S (1996) Enantioselective synthesis of curacin A. 2. Total synthesis of curacin A by condensation of C1-C7, C8-C17, and C18-C22 segments. Tetrahedron Lett 37:1799-1800.
18. Kang G-J, Getahun Z, Muzaffar A, Brossi A, and Hamel E (1990) N-acetylcolchinol O-methyl ether and thiocolchicine, potent analogs of colchicine modified in the C ring: evaluation of the mechanistic basis for their enhanced biological properties. J Biol Chem 265:10255-10259.
19. Kier LB and Hall LH (1986) Molecular Connectivity in Structure-Activity Analysis. John Wiley and Sons, New York.
20. Lai J-Y, Yu J, Mekonnen B, and Falck JR (1996) Synthesis of curacin A, an antimitotic cyclopropane-thiazoline from the marine cyanobacterium Lyngbya majuscula. Tetrahedron Lett 37:7167-7170.
21. Lessinger L and Margulis TN (1978) The crystal structure of colchicine. A new application of magic integers to multiple-solution direct methods. Acta Cryst B34:578-584.
22. Ludueña RF and Roach MC (1991) Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmacol Ther 49:133-152.
23. Ludueña RF, Prasad V, Roach MC, Banerjee M, Yoo H-D, and Gerwick WH (1997) Interaction of the cyanobacterial thiazoline-containing lipid curacin A with bovine brain tubulin. Drug Dev Res 40:223-229.
24. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, and Boyd M (1991) Feasibility of a high-flux anticancer drug screen utilizing a diverse panel of human tumor cell lines in culture. J Natl Cancer Inst 83:757-766.
25. Nagle DG, Geralds RS, Yoo H-D, Gerwick WH, Kim T-S, Nambu M, and White JD (1995) Absolute configuration of curacin A, a novel antimitotic agent from the tropical marine cyanobacterium Lyngbya majuscula. Tetrahedron Lett 36:1189-1192.
26. Onoda T, Shirai R, Koiso Y, and Iwasaki S (1996a) Asymmetric total synthesis of curacin A. Tetrahedron Lett 37:4397-4400.
27. Onoda T, Shirai R, Koiso Y, and Iwasaki S (1996b) Synthetic study of curacin A: a novel antimitotic agent from the cyanobacterium Lyngbya majuscula. Tetrahedron 52:14543-14562.
28. Pack A, Jordan MA, Gerwick W, Jacobs RS, and Wilson L (1995) Curacin A, a new potent antimitotic marine natural product, increases dynamic instability of microtubules. Proc Am Assoc Cancer Res 36:455.
29. Rogers D and Hopfinger AJ (1994) Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J Chem Inf Comp Sci 34:854-866.
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
31. ter Haar E, Rosenkranz HS, Hamel E, and Day BW (1996) Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents. Bioorg Med Chem 4:1659-1671.
32. White JD, Kim T-S, and Nambu M (1995) Synthesis of curacin A: a powerful antimitotic from the cyanobacterium Lyngbya majuscula. J Am Chem Soc 117: 5612-5613.
33. White JD, Kim T-S, and Nambu M (1997) Absolute configuration and total synthesis of (+)-curacin A, an antiproliferative agent from the cyanobacterium Lyngbya majuscula. J Am Chem Soc 119:103-111.
34. Wilson L and Jordan MA (1995) Microtubule dynamics: taking aim at a moving target. Chem Biol 2:569-573.
35. Wipf P and Xu W (1996) Total synthesis of the antimitotic marine natural product (+)-curacin A. J Org Chem 61:6556-6562.
36. Yoo H-D and Gerwick WH (1995) Curacins B and C, new antimitotic natural products from the marine cyanobacterium Lyngbya majuscula. J Nat Prod 58: 1961-1965.